TransMedics Group, Inc.
TMDX
$87.72
-$0.52-0.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 49.83% | 63.72% | 117.87% | 133.07% | 158.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.83% | 63.72% | 117.87% | 133.07% | 158.72% |
| Cost of Revenue | 49.21% | 85.95% | 186.47% | 188.46% | 211.56% |
| Gross Profit | 50.27% | 49.64% | 88.51% | 108.45% | 131.48% |
| SG&A Expenses | 44.06% | 39.16% | 46.12% | 44.74% | 49.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.55% | 55.19% | 90.73% | 93.45% | 100.69% |
| Operating Income | 87.79% | 449.33% | 1,480.57% | 694.59% | 167.90% |
| Income Before Tax | 80.92% | 115.76% | 1,340.10% | 572.11% | 157.65% |
| Income Tax Expenses | 178.57% | 101.92% | -295.24% | 1,681.82% | -984.21% |
| Earnings from Continuing Operations | 70.11% | 116.58% | 1,318.18% | 562.71% | 159.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.11% | 116.58% | 1,318.18% | 562.71% | 159.99% |
| EBIT | 87.79% | 449.33% | 1,480.57% | 694.59% | 167.90% |
| EBITDA | 74.51% | 1,081.82% | 3,419.96% | 2,185.16% | 249.40% |
| EPS Basic | 65.26% | 116.18% | 1,295.45% | 555.69% | 158.84% |
| Normalized Basic EPS | 15.76% | 1,368.52% | 1,319.68% | 564.44% | 186.19% |
| EPS Diluted | 76.83% | 115.38% | 1,236.36% | 528.40% | 153.88% |
| Normalized Diluted EPS | 15.76% | 1,277.78% | 1,244.68% | 538.90% | 182.27% |
| Average Basic Shares Outstanding | 2.91% | 2.54% | 1.76% | 1.55% | 1.98% |
| Average Diluted Shares Outstanding | 3.02% | 9.41% | 8.43% | 7.50% | 6.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |